Overview

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

Status:
RECRUITING
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.
Phase:
PHASE1
Details
Lead Sponsor:
ADARx Pharmaceuticals, Inc.
Collaborators:
ADARx Australia Pty Ltd
Avance Clinical Pty Ltd.
Treatments:
RNA, Small Interfering